AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7246688 — intervention group
Group type: COMPARATOR
Intervention: Standard midtrimester amniocentesis without ultrasound
Number of subjects: 0
Study 6376030 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary treatment with energy and carbohydrate restriction
Number of subjects: 38
Study 6376030 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide and chlorpropamide
Number of subjects: 38
Study 6376030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 6376030 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 38
Study 31661346 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Psychological Therapy (IPT)
Number of subjects: 40
Study 31661346 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TaU)
Number of subjects: 40
Study 29868916 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (cholecalciferol)
Number of subjects: 2994
Study 27843084 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 1%
Number of subjects: 49
Study 27843084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclopentolate 1%
Number of subjects: 49
Study 27843084 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 49
Study 24527596 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMFs) once a day for 30 days
Number of subjects: 43
Study 24527596 — intervention group
Group type: COMPARATOR
Intervention: Conventional drug therapy
Number of subjects: 43
Study 22323376 — intervention group
Group type: EXPERIMENTAL
Intervention: Validating communication
Number of subjects: 28
Study 22323376 — intervention group
Group type: COMPARATOR
Intervention: Invalidating communication
Number of subjects: 28
Study 19996813 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac tromethamine 0.4% (one drop twice a day for 2 weeks)
Number of subjects: 12
Study 19996813 — intervention group
Group type: COMPARATOR
Intervention: artificial tear solution (placebo, used for 2 weeks)
Number of subjects: 12
Study 18004596 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 1-2 mg
Number of subjects: 27
Study 18004596 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 25-50 mg
Number of subjects: 27
Study 18004596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 16897906 — intervention group
Group type: EXPERIMENTAL
Intervention: Live music therapy
Number of subjects: 14
Study 16897906 — intervention group
Group type: COMPARATOR
Intervention: Verbal interaction (Control)
Number of subjects: 14
Study 14574083 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI perindopril
Number of subjects: 36
Study 14574083 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB candesartan
Number of subjects: 36
Study 14574083 — intervention group
Group type: COMPARATOR
Intervention: Control (without perindopril and candesartan)
Number of subjects: 36
Study 10784228 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg nateglinide (single oral dose, given 20 min prior to IGTT)
Number of subjects: 10
Study 10784228 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 10
Study 8769510 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine hydrochloride infusion (0.5 g/kg for 30 minutes)
Number of subjects: 10
Study 1563948 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic relaxation
Number of subjects: 17
Study 1563948 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive relaxation
Number of subjects: 17
Study 1563948 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic plus progressive relaxation
Number of subjects: 17
Study 1563948 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 17
Study 3902588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (200 mg at lunch, 400 mg at bedtime)
Number of subjects: 107
Study 3902588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 3902588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 107
Study 31244692 — intervention group
Group type: EXPERIMENTAL
Intervention: Robin (16 weekly individual sessions + a minimum of 4 family sessions)
Number of subjects: 30
Study 31244692 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (active control group)
Number of subjects: 30
Study 30419893 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus the DATES text message intervention
Number of subjects: 572
Study 30419893 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 572
Study 25891220 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 80
Study 25891220 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 80
Study 25891220 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine-extended release
Number of subjects: 80
Study 25891220 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 80
Study 25891220 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonremitters
Number of subjects: 80
Study 24874737 — intervention group
Group type: EXPERIMENTAL
Intervention: Knocking down of the α‐synuclein gene
Number of subjects: 0
Study 24874737 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy deprivation
Number of subjects: 0
Study 24874737 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐methyladenine or ATG5 knocking down
Number of subjects: 0
Study 24874737 — intervention group
Group type: EXPERIMENTAL
Intervention: T lymphocytes from patients with systemic lupus erythematosus
Number of subjects: 0
Study 22851072 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion with TCI vein pump (Group B)
Number of subjects: 120
Study 22851072 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil vein infusion with PCA pump (Group C)
Number of subjects: 120
Study 22851072 — intervention group
Group type: COMPARATOR
Intervention: Non-anaesthesia (Group A)
Number of subjects: 120
Study 20151090 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention program
Number of subjects: 393
Study 18665819 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% alcoholic chlorhexidine gluconate (alcoholic CG)
Number of subjects: 631
Study 18665819 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% aqueous chlorhexidine gluconate (aqueous CG)
Number of subjects: 631
Study 18665819 — intervention group
Group type: COMPARATOR
Intervention: 10% aqueous povidone iodine (aqueous PI)
Number of subjects: 631
Study 16422893 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 degrees C saline
Number of subjects: 122
Study 16422893 — intervention group
Group type: COMPARATOR
Intervention: 37 degrees C saline
Number of subjects: 122
Study 16422893 — intervention group
Group type: COMPARATOR
Intervention: 15 degrees C saline
Number of subjects: 122
Study 16422893 — intervention group
Group type: COMPARATOR
Intervention: 20 degrees C saline
Number of subjects: 122
Study 12859114 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide for 1 h/day for 21 days
Number of subjects: 60
Study 12859114 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide for 7 h/day for 21 days
Number of subjects: 60
Study 12859114 — intervention group
Group type: COMPARATOR
Intervention: Control (nontreated specimens)
Number of subjects: 60
Study 10649262 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (oral cancer screening)
Number of subjects: 59994
Study 10649262 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 59994
Study 8618580 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa
Number of subjects: 103
Study 8618580 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 103
Study 1535816 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms HBs antigen vaccine
Number of subjects: 80
Study 1535816 — intervention group
Group type: COMPARATOR
Intervention: Other hepatitis B vaccine
Number of subjects: 80
Study 6150660 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg ketamine intravenously
Number of subjects: 20
Study 6150660 — intervention group
Group type: COMPARATOR
Intervention: 5.0 mg/kg thiopental intravenously
Number of subjects: 20
Study 30243234 — intervention group
Group type: EXPERIMENTAL
Intervention: FES cycling exercise
Number of subjects: 11
Study 30243234 — intervention group
Group type: COMPARATOR
Intervention: Passive leg cycling (PLC)
Number of subjects: 11
Study 29201390 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Written Disclosure (PWD)
Number of subjects: 60
Study 29201390 — intervention group
Group type: COMPARATOR
Intervention: Neutral writing control
Number of subjects: 60
Study 29201390 — intervention group
Group type: COMPARATOR
Intervention: No writing condition
Number of subjects: 60
Study 26654250 — intervention group
Group type: EXPERIMENTAL
Intervention: PREPARE website and easy-to-read advance directive
Number of subjects: 0
Study 26654250 — intervention group
Group type: COMPARATOR
Intervention: Advance directive only (Control)
Number of subjects: 0
Study 23569301 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus chemotherapy (FOLFIRI or mFOLFOX6)
Number of subjects: 138
Study 23569301 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 138
Study 23569301 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus chemotherapy (FOLFIRI or mFOLFOX6) with resection of liver metastases
Number of subjects: 138
Study 23569301 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone without resection
Number of subjects: 138
Study 21860843 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational drug (seven doses)
Number of subjects: 202
Study 21860843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 21860843 — intervention group
Group type: COMPARATOR
Intervention: Active comparator
Number of subjects: 202
Study 17936405 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiral CT
Number of subjects: 2472
Study 17936405 — intervention group
Group type: COMPARATOR
Intervention: Control (yearly clinical examination)
Number of subjects: 2472
Study 16785190 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy
Number of subjects: 92
Study 12540116 — intervention group
Group type: EXPERIMENTAL
Intervention: OneGloss (OG)
Number of subjects: 32
Study 12540116 — intervention group
Group type: EXPERIMENTAL
Intervention: Super‐Snap system (SS)
Number of subjects: 32
Study 12540116 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot Carbides (RC)
Number of subjects: 32
Study 12540116 — intervention group
Group type: EXPERIMENTAL
Intervention: CompoSite Polishers (CS)
Number of subjects: 32
Study 12540116 — intervention group
Group type: EXPERIMENTAL
Intervention: Finishing/polishing techniques (general)
Number of subjects: 32
Study 10952804 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic haemostasis using single-modality treatments (injection agents such as epinephrine, sclerosants, thrombogenic substances, or thermal therapies)
Number of subjects: 0
Study 10952804 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy involving injection and thermal techniques
Number of subjects: 0
Study 10952804 — intervention group
Group type: COMPARATOR
Intervention: Meta-analyses of controlled trials
Number of subjects: 0
Study 8866311 — intervention group
Group type: EXPERIMENTAL
Intervention: KCl/MFP
Number of subjects: 56
Study 8866311 — intervention group
Group type: EXPERIMENTAL
Intervention: NaMFP
Number of subjects: 56
Study 8866311 — intervention group
Group type: EXPERIMENTAL
Intervention: SrAc2F
Number of subjects: 56
Study 1627020 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 3796
Study 1627020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3796
Study 6375465 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg buprenorphine
Number of subjects: 158
Study 6375465 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg buprenorphine
Number of subjects: 158
Study 6375465 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg buprenorphine after bupivacaine
Number of subjects: 158
Study 6375465 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reinjection)
Number of subjects: 158
Study 6375465 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 158
Study 31147243 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative depression care management intervention
Number of subjects: 2351
Study 31147243 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 2351
Study 29970139 — intervention group
Group type: EXPERIMENTAL
Intervention: HAL training
Number of subjects: 19
Study 29970139 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 19
Study 25432493 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder neck plication stitch
Number of subjects: 158
Study 25432493 — intervention group
Group type: COMPARATOR
Intervention: No bladder neck plication stitch
Number of subjects: 158
Study 24370820 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (lateral position with injected arm down and 20° Trendelenburg position)
Number of subjects: 50
Study 24370820 — intervention group
Group type: COMPARATOR
Intervention: Group I (supine position)
Number of subjects: 50
Study 23023905 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation (3 capsules per day: eicosapentaenoic acid 1,548 mg; docosahexaenoic acid 828 mg; other omega-3 fatty acids 338 mg)
Number of subjects: 84
Study 23023905 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules (sunflower oil 2,100 mg)
Number of subjects: 84
Study 19778673 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) + Optimal medical therapy (OMT)
Number of subjects: 2285
Study 19778673 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT) alone
Number of subjects: 2285
Study 17536129 — intervention group
Group type: EXPERIMENTAL
Intervention: Blueberry (12.5 mmole Trolox Equivalents (TE) AOC)
Number of subjects: 50
Study 17536129 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed grape powder (39.9 mmole TE AOC)
Number of subjects: 50
Study 17536129 — intervention group
Group type: EXPERIMENTAL
Intervention: Cherries (280 g, 4.5 mmol TE AOC)
Number of subjects: 50
Study 17536129 — intervention group
Group type: COMPARATOR
Intervention: Control groups with additional macronutrients (Studies #4 and #5)
Number of subjects: 50
Study 17536129 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried plums or dried plum juice
Number of subjects: 50
Study 15132730 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (NA) plus Vitamin E
Number of subjects: 64
Study 15132730 — intervention group
Group type: COMPARATOR
Intervention: Nicotinamide (NA)
Number of subjects: 64
Study 11488362 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR (75-225 mg/day)
Number of subjects: 92
Study 11488362 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20-60 mg/day)
Number of subjects: 92
Study 11488362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 9733153 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA and DHA ethyl esters (2.04 g EPA and 1.4 g DHA)
Number of subjects: 32
Study 9733153 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (4 g/day)
Number of subjects: 32
Study 8778189 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 27
Study 8778189 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin
Number of subjects: 27
Study 2256489 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol (0.035 mg)‐norethindrone (0.40 mg)
Number of subjects: 156
Study 2256489 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol (0.030 to 0.040 mg)‐levonorgestrel (0.050 to 0.125 mg)
Number of subjects: 156
Study 2256489 — intervention group
Group type: COMPARATOR
Intervention: non‐oral‐contraceptive group
Number of subjects: 156
Study 2256489 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 156
Study 582998 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,3,7-trimethyl-xanthine (caffeine)
Number of subjects: 0
Study 582998 — intervention group
Group type: COMPARATOR
Intervention: Control (no caffeine)
Number of subjects: 0
Study 30985709 — intervention group
Group type: COMPARATOR
Intervention: Custom-made LSO with metallic stays (C group)
Number of subjects: 73
Study 30985709 — intervention group
Group type: COMPARATOR
Intervention: Ready-made LSO without metallic stays (R group)
Number of subjects: 73
Study 30985709 — intervention group
Group type: COMPARATOR
Intervention: No LSO (N group)
Number of subjects: 73
Study 26701153 — intervention group
Group type: EXPERIMENTAL
Intervention: TV only
Number of subjects: 15600
Study 26701153 — intervention group
Group type: EXPERIMENTAL
Intervention: TV plus community activations
Number of subjects: 15600
Study 26701153 — intervention group
Group type: COMPARATOR
Intervention: Control (non-randomised)
Number of subjects: 15600
Study 23522152 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic exposure based on clinical presentation of UTI, pyuria, and procalcitonin (PCT) levels.
Number of subjects: 250
Study 23522152 — intervention group
Group type: EXPERIMENTAL
Intervention: Proadrenomedullin (ProADM) integrated into an interdisciplinary assessment bundle.
Number of subjects: 250
Study 23522152 — intervention group
Group type: COMPARATOR
Intervention: Control group conforming to the guidelines.
Number of subjects: 250
Study 20496000 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally and linguistically appropriate interventions to increase hepatitis B knowledge, serologic testing, and vaccination.
Number of subjects: 97
Study 19453311 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally disintegrating ondansetron
Number of subjects: 109
Study 19453311 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron
Number of subjects: 109
Study 19453311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 16430540 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 80
Study 16430540 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol + Esmolol
Number of subjects: 80
Study 16430540 — intervention group
Group type: COMPARATOR
Intervention: Metohexital
Number of subjects: 80
Study 16430540 — intervention group
Group type: EXPERIMENTAL
Intervention: Metohexital + Esmolol
Number of subjects: 80
Study 15261895 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (Body and Soul program)
Number of subjects: 0
Study 15261895 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 11737100 — intervention group
Group type: EXPERIMENTAL
Intervention: SLA implants
Number of subjects: 32
Study 9086420 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 gel and membrane stripping
Number of subjects: 150
Study 9086420 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo gel and membrane stripping
Number of subjects: 150
Study 9086420 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 gel and no membrane stripping
Number of subjects: 150
Study 9086420 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel and no membrane stripping
Number of subjects: 150
Study 1375082 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin-mineral supplement
Number of subjects: 62
Study 1375082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 4057126 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological group treatment aimed at weight reduction, improvement of stress coping, and reduction of salt‐intake, conducted over 16 therapy sessions by trained lay therapists.
Number of subjects: 261
Study 4057126 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group (no specific intervention mentioned).
Number of subjects: 261
Study 31404055 — intervention group
Group type: EXPERIMENTAL
Intervention: activL Artificial Disc
Number of subjects: 324
Study 31404055 — intervention group
Group type: COMPARATOR
Intervention: Control TDR (ProDisc-L or Charité)
Number of subjects: 324
Study 29283931 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (R)
Number of subjects: 0
Study 29283931 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 0
Study 29283931 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval aerobic training (IA)
Number of subjects: 0
Study 26359780 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual training group
Number of subjects: 0
Study 26359780 — intervention group
Group type: COMPARATOR
Intervention: Sudden training group
Number of subjects: 0
Study 24612497 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) program in intervention nursing homes
Number of subjects: 575
Study 24612497 — intervention group
Group type: COMPARATOR
Intervention: Control region (no ACP program)
Number of subjects: 575
Study 22686512 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with adrenaline (40 mL, 2.5 mg/mL bupivacaine and 5 μg/mL adrenaline)
Number of subjects: 260
Study 22686512 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (40 mL, 0.9%)
Number of subjects: 260
Study 20491047 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical mydriasis
Number of subjects: 90
Study 20491047 — intervention group
Group type: EXPERIMENTAL
Intervention: Mydriasert
Number of subjects: 90
Study 20491047 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral mydriasis
Number of subjects: 90
Study 17907480 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Sensitive Multi Protection Toothpaste (5.5% potassium citrate)
Number of subjects: 75
Study 17907480 — intervention group
Group type: COMPARATOR
Intervention: Sensodyne Total Care F Toothpaste (3.75% potassium chloride)
Number of subjects: 75
Study 16232082 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin (0.5 mg/kg per day)
Number of subjects: 18
Study 16232082 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-diseased, n=22)
Number of subjects: 18
Study 12090747 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin dalteparin
Number of subjects: 629
Study 12090747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 629